Theralase Provides Update on 2016 Strategic Initiatives

Theralase Provides Update on 2016 Strategic Initiatives

The PDT division is focused on commencing and successfully completing a Phase Ib clinical trial for patients afflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”) utilizing its novel next generation light-activated, anticancer drug, TLD-1433.

(Visited 2 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.